Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD

• Published in: Chest Vol. 151; no. 2; p. 340
• Main Authors: Martinez, Fernando J, Rabe, Klaus F, Ferguson, Gary T, Fabbri, Leonardo M, Rennard, Stephen, Feldman, Gregory J, Sethi, Sanjay, Spangenthal, Selwyn, Gottschlich, Gregory M, Rodriguez-Roisin, Roberto, Arora, Samir, Siler, Thomas M, Siddiqui, Shahid, Darken, Patrick, Fischer, Tracy, Maes, Andrea, Golden, Michael, Orevillo, Chad, Reisner, Colin
• Format: Journal Article
• Language: English
• Published: United States 01.02.2017
• Subjects: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents - administration & dosage; Budesonide - therapeutic use; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Fluticasone - therapeutic use; Forced Expiratory Volume; Formoterol Fumarate - administration & dosage; Glucocorticoids - therapeutic use; Glycopyrrolate - administration & dosage; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists - administration & dosage; Prednisone - therapeutic use; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - physiopathology; Suspensions; Vital Capacity; muscarinic antagonists; chronic bronchitis; β-agonist; bronchodilator; emphysema

Long-acting muscarinic antagonist (LAMA)/long-acting β -agonist (LABA) combinations are a treatment option for patients with COPD who continue to have symptoms despite treatment with a LAMA or a LABA alone. The Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe C...